| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.56B+6.5% | $1.47B+36.7% | $1.07B+97.2% | $544.0M+6.5% | $511.0M-89.5% | $4.88B-7.1% | $5.25B+0.8% | $5.21B+10.6% | $4.71B+24.8% | $3.77B |
| Cost of revenue | $1.10B+0.1% | $1.10B+32.5% | $830.0M+90.4% | $436.0M+12.1% | $389.0M-87.2% | $3.05B-4.9% | $3.20B+0.7% | $3.18B+11.2% | $2.86B+23.9% | $2.31B |
| Gross profit | $3.48B+8.2% | $3.21B+18.2% | $2.72B+30.4% | $2.08B+5.5% | $1.98B+7.9% | $1.83B-10.6% | $2.05B+1.0% | $2.03B+9.7% | $1.85B+26.3% | $1.46B |
| Selling, general and administrative expenses | $1.92B+0.6% | $1.91B+8.8% | $1.76B+43.2% | $1.23B+4.1% | $1.18B+3.1% | $1.14B-1.3% | $1.16B-0.3% | $1.16B+6.6% | $1.09B+19.1% | $914.0M |
| Research and development expenses | $226.0M-1.7% | $230.0M-0.9% | $232.0M+12.6% | $206.0M+1.0% | $204.0M+9.1% | $187.0M-2.1% | $191.0M+1.1% | $189.0M+4.4% | $181.0M+64.5% | $110.0M |
| Restructuring and asset impairment charges | $103.0M+66.1% | $62.0M-18.4% | $76.0M+162.1% | $29.0M+314.3% | $7.0M-90.7% | $75.0M+19.0% | $63.0M+186.4% | $22.0M-12.0% | $25.0M-16.7% | $30.0M |
| Operating income | $1.22B+21.2% | $1.01B+54.8% | $652.0M+4.8% | $622.0M+6.3% | $585.0M+59.4% | $367.0M-24.5% | $486.0M-25.7% | $654.0M+18.5% | $552.0M+35.3% | $408.0M |
| Interest expense | -$29.0M+34.1% | -$44.0M+10.2% | -$49.0M-198.0% | $50.0M-34.2% | $76.0M-1.3% | $77.0M+14.9% | $67.0M-18.3% | $82.0M+0.0% | $82.0M+17.1% | $70.0M |
| Gain on remeasurement of previously held equity interest | $0-100.0% | $152.0M | $0 | $0 | — | — | — | — | — | — |
| Other non-operating income, net | $18.0M+12.5% | $16.0M-51.5% | $33.0M+371.4% | $7.0M | $0+100.0% | -$5.0M-25.0% | -$4.0M-130.8% | $13.0M+116.7% | $6.0M+200.0% | $2.0M |
| Loss on sale of businesses | -$31.0M+32.6% | -$46.0M-4500.0% | -$1.0M-200.0% | $1.0M-50.0% | $2.0M | $0-100.0% | $1.0M | $0+100.0% | -$10.0M | $0 |
| Income before taxes | $1.18B+8.6% | $1.09B+71.2% | $635.0M+44.3% | $440.0M-13.9% | $511.0M+79.3% | $285.0M-31.5% | $416.0M-28.9% | $585.0M+25.5% | $466.0M+37.1% | $340.0M |
| Income tax expense | -$231.0M-17.3% | -$197.0M-657.7% | -$26.0M-130.6% | $85.0M+1.2% | $84.0M+171.0% | $31.0M+106.7% | $15.0M-58.3% | $36.0M-73.5% | $136.0M+70.0% | $80.0M |
| Net income | $950.0M+6.7% | $890.0M+46.1% | $609.0M+71.5% | $355.0M-16.9% | $427.0M+68.1% | $254.0M-36.7% | $401.0M-27.0% | $549.0M+66.4% | $330.0M+26.9% | $260.0M |
| Net loss attributable to non-controlling interests | $7.0M | $0 | $0 | — | — | — | — | — | -$1.0M | $0 |
| Net income attributable to Xylem | $957.0M+7.5% | $890.0M+46.1% | $609.0M | — | — | — | — | — | $331.0M+27.3% | $260.0M |
| Basic (in dollars per share) | $3930000.00+7.1% | $3670000.00+30.6% | $2810000.00+42.6% | $1970000.00-16.9% | $2370000.00+68.1% | $1410000.00-36.8% | $2230000.00-26.9% | $3050000.00+65.8% | $1840000.00+26.9% | $1450000.00 |
| Diluted (in dollars per share) | $3920000.00+7.4% | $3650000.00+30.8% | $2790000.00+42.3% | $1960000.00-16.6% | $2350000.00+67.9% | $1400000.00-36.7% | $2210000.00-27.1% | $3030000.00+65.6% | $1830000.00+26.2% | $1450000.00 |
| Basic (in shares) | 243.37B+0.3% | 242.58B+11.8% | 217.01B+20.4% | 180.22B-0.0% | 180.25B+0.1% | 180.12B+0.1% | 179.99B+0.1% | 179.78B+0.1% | 179.63B+0.3% | 179.11B |
| Diluted (in shares) | 243.99B+0.2% | 243.52B+11.6% | 218.18B+20.6% | 180.98B-0.3% | 181.53B+0.2% | 181.10B-0.1% | 181.20B+0.0% | 181.13B+0.2% | 180.86B+0.5% | 180.04B |
| Product | ||||||||||
| Service | ||||||||||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.